Eisai Enters Vietnam With a Subsidiary

Japanese pharma Eisai Co., Ltd announced a pharmaceutical sales subsidiary in Ho Chi Minh, Vietnam on September 14, 2020. With Vietnam emerging as a sizeable market within South East Asia, the pharmaceutical market clocked in +10.6% compound annual growth from 2014 to 2019.

By Sahana Shankar, Ph.D. Candidate

The expected growth rate is estimated to continue in double digits for the coming years, owing to the expansion of middle-income groups and an increase in non-communicable diseases.

Eisai (Thailand) Marketing Co., Ltd operated in Vietnam through a local agency since 1992. In 1995, Eisai established a representative office in Ho Chi Minh City, with proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy drug Mathylcobal, among others.

With Eisai Vietnam, Eisai targets enhanced sales in Vietnam and the delivery of innovative drugs to patients. Eisai launched a new anti-epileptic drug Fycompa in 2019 and has anti-cancer agents, Lenvima and Halaven at different regulatory processes levels.

Eisai Co., Ltd is a pharmaceutical company headquartered in Tokyo, Japan, with a global network of 10,000 employees, R&D facilities, manufacturing, and marketing subsidiaries focusing on neurology and oncology products.

Related Article: Eisai Obtains Novel Anti-Cancer Molecules via PRISM BioLab Contract

Reference:

https://www.eisai.com/news/2020/news202055.html

Author

Sahana Shankar